The Coverage and Analysis Group at the Centers for Medicare and Medicaid Services (CMS) requested this report from The Technology Assessment Program (TAP) at the Agency for Healthcare Research and Quality (AHRQ). AHRQ assigned this report to the following Evidence-based Practice Center: Tufts EPC (Contract No. 290 2007 10055 I).
Prostate cancer is the most common noncutaneous malignancy diagnosed in men in the United States. The vast majority of patients diagnosed today have clinically localized prostate cancer (T1-T2N0), which is the subject of this report. A Comparative Effectiveness Review of Therapies for Clinically Localized Prostate Cancer was undertaken on behalf of the Agency for Healthcare Research and Quality (AHRQ) by the Minnesota Evidence-based Practice Center (EPC) in 2007 (Wilt et al. Comparative effectiveness of therapies for clinically localized prostate cancer. Comparative Effectiveness Review No. 13, prepared by Minnesota Evidence-based Practice Center under contract no. 290-02-0009 Rockville, MD: Agency for Healthcare Research and Quality, February 2008. Available at